CLSDClearside Biomedical, Inc.

Nasdaq clearsidebio.com


$ 1.06 $ 0.09 (9.28 %)    

Monday, 09-Sep-2024 15:59:40 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 1.06
$ 0.99
$ 1.06 x 447
-- x --
$ 0.99 - $ 1.10
$ 0.65 - $ 2.12
510,404
na
79.23M
$ 1.55
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-12-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-14-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-11-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-10-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-15-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 03-13-2020 12-31-2019 10-K
20 11-08-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 03-14-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-16-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-11-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-12-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-clearside-biomedical-maintains-5-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $5 price target.

 chardan-capital-initiates-coverage-on-clearside-biomedical-with-buy-rating-announces-price-target-of-6

Chardan Capital analyst Daniil Gataulin initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Buy rating and annou...

 hc-wainwright--co-reiterates-buy-on-clearside-biomedical-maintains-5-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $5 price target.

 needham-reiterates-buy-on-clearside-biomedical-maintains-4-price-target

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.

 clearside-biomedical-q2-2024-adj-eps-010-beats-013-estimate-sales-9000k-miss-15200k-estimate

Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-clearside-biomedical-maintains-5-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $5 price target.

 needham-reiterates-buy-on-clearside-biomedical-maintains-4-price-target

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.

 why-is-clearside-biomedical-stock-gaining-today

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer ra...

 oppenheimer-initiates-coverage-on-clearside-biomedical-with-outperform-rating-announces-price-target-of-5

Oppenheimer analyst Andreas Argyrides initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Outperform rating and ...

 clearside-biomedical-announces-publication-of-consensus-guidelines-for-drug-delivery-via-suprachoroidal-space-injection-in-peer-reviewed-industry-journal-retina

Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic ...

 hc-wainwright--co-maintains-buy-on-clearside-biomedical-lowers-price-target-to-5

HC Wainwright & Co. analyst Yi Chen maintains Clearside Biomedical (NASDAQ:CLSD) with a Buy and lowers the price target ...

 needham-reiterates-buy-on-clearside-biomedical-maintains-4-price-target

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.

 clearside-biomedical-q1-2024-gaap-eps-017-misses-014-estimate-sales-230000k-miss-585000k-estimate

Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION